#Taiwan #Taipei #ADC #Mycenax Biotech #RIN Institute

Mycenax Biotech and RIN Form Strategic Alliance for ADC Development

In a significant development for the biopharmaceutical industry, Mycenax Biotech Inc., a leading provider of biological contract development and manufacturing (CDMO) services based in Taiwan, has signed a licensing agreement with Japan’s RIN Institute Inc. This strategic partnership grants Mycenax the rights to utilize RIN’s proprietary Val-Leu-Lys (VLK) linker technology on a global scale within its CDMO services.

The Significance of the Agreement

The linker technology VLK from RIN is noteworthy for its demonstrated efficacy in targeting tumors and its high serum stability. This advancement allows for the development of sophisticated antibody-drug conjugates (ADCs) that hold the promise of improving cancer treatment efficacy. Specifically, the VLK linker enhances cytotoxicity through dual mechanisms in the tumor microenvironment, significantly boosting the internalization process of ADCs. This agreement positions Mycenax to deliver tailored ADC solutions to its pharmaceutical partners around the world.

Pei-Jiun Chen, CEO and Chairman of Mycenax, expressed enthusiasm regarding the agreement, highlighting its importance as a milestone in their ongoing mission to provide innovative and competitive ADC solutions. “This collaboration strengthens our technical capabilities and enhances our commitment to advancing next-generation ADC therapies,” said Chen.

The collaboration is a follow-up to a memorandum of understanding signed on April 7, 2025, which paved the way for increased cooperation between the two organizations, with a focus on fostering innovation in the ADC space.

About RIN Institute

Established in January 2016, RIN Institute specializes in the research and development of cancer-targeting antibodies for therapeutic and diagnostic applications. The institute was founded based on research outcomes from Dr. Yasuhiro Matsumura, a former chief of the development therapies division at the National Cancer Center (NCC) in Japan. In the same year, RIN was recognized as a biotechnology firm derived from NCC, with its research lab serving as a base for effective collaboration with the center. RIN’s ongoing projects include the development of ADCs and powerful new thrombolytic fusion proteins. As of January 2023, RIN began Phase 1 trials of a humanized anti-TMEM180 antibody at NCC, aiming to accelerate the development of innovative cancer treatments and diagnostics.

About Mycenax Biotech

Mycenax Biotech Inc. is a premier CDMO in Taiwan, providing integrated biological solutions ranging from cell line development to pharmaceutical product manufacturing. The company operates two Good Manufacturing Practice (GMP)-compliant facilities inspected and approved by international regulatory authorities, including the European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), Ministry of Food and Drug Safety (MFDS), and Health Canada.

In collaboration with KriSan Biotech and Spera Pharma, Mycenax is enhancing its ADC offerings by leveraging recognized expertise in site-specific conjugation and multi-arm linkers, which better addresses the growing needs of global markets. Additionally, the company partners with Alfresa Holdings, Kidswell Bio, and Chiome Bioscience as part of the Japanese Ministry of Health, Labour and Welfare (MHLW) grant program for the production of biosimilars. For further information, visit Mycenax's website.

Through this agreement, Mycenax Biotech and RIN Institute are set to further propel the development and accessibility of advanced cancer therapies, making significant strides towards more effective treatment options for patients worldwide.